BDSI Stock - BioDelivery Sciences International, Inc.
Unlock GoAI Insights for BDSI
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|
| Revenue | $166.70M | $156.47M | $111.39M | $55.64M | $61.98M |
| Gross Profit | $143.33M | $131.81M | $89.80M | $39.86M | $42.49M |
| Gross Margin | 86.0% | 84.2% | 80.6% | 71.6% | 68.5% |
| Operating Income | $37.12M | $32.98M | $3.74M | $-23,648,000 | $-29,420,000 |
| Net Income | $84.86M | $25.71M | $-15,305,000 | $-33,867,000 | $5.29M |
| Net Margin | 50.9% | 16.4% | -13.7% | -60.9% | 8.5% |
| EPS | $0.82 | $0.26 | $-0.18 | $-0.54 | $0.10 |
BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; and Symproic, a peripherally acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation. The company also provides ELYXYB, a celecoxib oral solution for the treatment of migraine with or without aura in adults; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in cancer patients. BioDelivery Sciences International, Inc. was incorporated in 1997 and is headquartered in Raleigh, North Carolina. As of March 18, 2022, BioDelivery Sciences International, Inc. operates as a subsidiary of Collegium Pharmaceutical, Inc.
Visit WebsiteEarnings History & Surprises
BDSIEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2022 | Mar 9, 2022 | $0.02 | $0.62 | +2483.3% | ✓ BEAT |
Q4 2021 | Nov 3, 2021 | $0.06 | $0.07 | +16.7% | ✓ BEAT |
Q3 2021 | Aug 4, 2021 | $0.05 | $0.09 | +80.0% | ✓ BEAT |
Q2 2021 | May 6, 2021 | $0.07 | $0.05 | -28.6% | ✗ MISS |
Q1 2021 | Mar 10, 2021 | $0.06 | $0.10 | +66.7% | ✓ BEAT |
Q4 2020 | Nov 5, 2020 | $0.06 | $0.09 | +50.0% | ✓ BEAT |
Q3 2020 | Aug 5, 2020 | $0.04 | $0.01 | -73.9% | ✗ MISS |
Q2 2020 | May 7, 2020 | $0.02 | $0.05 | +207.7% | ✓ BEAT |
Q1 2020 | Mar 12, 2020 | $0.01 | $0.04 | +300.0% | ✓ BEAT |
Q4 2019 | Nov 12, 2019 | $0.00 | $0.00 | +100.6% | ✓ BEAT |
Q3 2019 | Aug 8, 2019 | $-0.06 | $-0.13 | -121.3% | ✗ MISS |
Q2 2019 | May 6, 2019 | $-0.08 | $-0.05 | +37.5% | ✓ BEAT |
Q1 2019 | Mar 14, 2019 | $-0.10 | $-0.08 | +20.0% | ✓ BEAT |
Q4 2018 | Nov 8, 2018 | $-0.13 | $-0.10 | +23.1% | ✓ BEAT |
Q3 2018 | Aug 9, 2018 | $-0.18 | $-0.16 | +11.1% | ✓ BEAT |
Q2 2018 | May 10, 2018 | $-0.21 | $-0.18 | +14.3% | ✓ BEAT |
Q1 2018 | Mar 15, 2018 | $-0.24 | $-0.29 | -20.8% | ✗ MISS |
Q4 2017 | Nov 9, 2017 | $-0.22 | $-0.21 | +4.5% | ✓ BEAT |
Q3 2017 | Aug 9, 2017 | $-0.24 | $-0.27 | -12.5% | ✗ MISS |
Q2 2017 | May 15, 2017 | $0.12 | $0.09 | -25.0% | ✗ MISS |
Latest News
Frequently Asked Questions about BDSI
What is BDSI's current stock price?
What is the analyst price target for BDSI?
What sector is BioDelivery Sciences International, Inc. in?
What is BDSI's market cap?
Does BDSI pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to BDSI for comparison